“Product Hopping” on Both Sides of the Pond: A Survey of U.S. and EU Case Law

This article is part of a Chronicle. See more from this Chronicle

Michael Frese, Ingrid Vandenborre, Julia York, Nov 24, 2014

In recent years, courts in both the United States and the European Union have increasingly been asked to consider under what circumstances the introduction of a new pharmaceutical drug product harms, rather than benefits, competition in contravention of the antitrust and competition laws. In the European Union, antitrust regulators have been active in challenging so-calle